thalidomide has been researched along with Epistaxis in 13 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Epistaxis: Bleeding from the nose.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-dose thalidomide seems to be safe and effective for the reduction of epistaxis in patients with hereditary haemorrhagic telangiectasia." | 9.20 | Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. ( Balduini, CL; Bastia, R; Bellistri, F; Benazzo, M; Chu, F; Danesino, C; Grignani, P; Invernizzi, R; Klersy, C; Matti, E; Olivieri, C; Ornati, F; Pagella, F; Plumitallo, S; Quaglia, F; Spinozzi, G, 2015) |
| " Thalidomide has been used as a therapeutic strategy for refractory epistaxis in hereditary haemorrhagic telangiectasia patients." | 8.98 | The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. ( Harrison, L; Jervis, P; Kundra, A, 2018) |
| "To evaluate the effectiveness of thalidomide for epistaxis in hereditary hemorrhagic telangiectasia (HHT), 7 HHT patients with recurrent epistaxis were treated with thalidomide at an initial dose of 50 mg/d, gradually increasing to 100 mg/d if needed." | 8.95 | Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study. ( Chen, X; Fang, J; Guan, J; Su, K; Ye, H; Zhang, W; Zhu, B, 2017) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 8.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " 67 received thalidomide, all for epistaxis and/or gastrointestinal bleeding; they received thalidomide for a mean of 13." | 7.91 | Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. ( Botella, LM; Buscarini, E; Dupuis-Girod, S; Geisthoff, U; Kjeldsen, AD; Mager, HJ; Pagella, F; Shovlin, CL; Suppressa, P; Zarrabeitia, R, 2019) |
| "In this work nasal powder formulations of thalidomide were designed and studied to be used by persons affected by hereditary hemorrhagic telangiectasia as a complementary anti-epistaxis therapy, with the goal of sustaining the effect obtained with thalidomide oral treatment after its discontinuation for adverse effects." | 7.83 | Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. ( Bettini, R; Bortolotti, F; Buttini, F; Chiapponi, V; Colombo, G; Colombo, P; Danesino, C; Invernizzi, R; Pagella, F; Quaglia, F; Rossi, A; Russo, P; Sonvico, F, 2016) |
| " We report here that treatment with thalidomide reduced the severity and frequency of nosebleeds (epistaxis) in the majority of a small group of subjects with HHT tested." | 7.76 | Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. ( Arthur, HM; Bréant, C; Disch, F; Eichmann, A; Freitas, C; Larrivée, B; Lebrin, F; Mager, JJ; Martin, S; Mathivet, T; Mummery, CL; Raymond, K; Snijder, RJ; Srun, S; Thomas, JL; van den Brink, S; Westermann, CJ, 2010) |
| "Thalidomide was recently reported to reduce the severity and frequency of epistaxes in patients with hereditary haemorrhagic telangiectasia (HHT)." | 5.37 | Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. ( Hermans, C; Lambert, C; Penaloza, A; Vekemans, MC, 2011) |
| "Low-dose thalidomide seems to be safe and effective for the reduction of epistaxis in patients with hereditary haemorrhagic telangiectasia." | 5.20 | Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. ( Balduini, CL; Bastia, R; Bellistri, F; Benazzo, M; Chu, F; Danesino, C; Grignani, P; Invernizzi, R; Klersy, C; Matti, E; Olivieri, C; Ornati, F; Pagella, F; Plumitallo, S; Quaglia, F; Spinozzi, G, 2015) |
| " In a few small studies, thalidomide was shown to consistently improve severity and frequency of epistaxis and improve hemoglobin concentrations while decreasing the need for transfusion." | 4.98 | Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. ( Clark, C; Halderman, AA; Invernizzi, R; Marple, BF; Poetker, DM; Reh, DD; Ryan, MW; Sindwani, R, 2018) |
| " Thalidomide has been used as a therapeutic strategy for refractory epistaxis in hereditary haemorrhagic telangiectasia patients." | 4.98 | The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. ( Harrison, L; Jervis, P; Kundra, A, 2018) |
| "To evaluate the effectiveness of thalidomide for epistaxis in hereditary hemorrhagic telangiectasia (HHT), 7 HHT patients with recurrent epistaxis were treated with thalidomide at an initial dose of 50 mg/d, gradually increasing to 100 mg/d if needed." | 4.95 | Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study. ( Chen, X; Fang, J; Guan, J; Su, K; Ye, H; Zhang, W; Zhu, B, 2017) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 4.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " 67 received thalidomide, all for epistaxis and/or gastrointestinal bleeding; they received thalidomide for a mean of 13." | 3.91 | Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. ( Botella, LM; Buscarini, E; Dupuis-Girod, S; Geisthoff, U; Kjeldsen, AD; Mager, HJ; Pagella, F; Shovlin, CL; Suppressa, P; Zarrabeitia, R, 2019) |
| "In this work nasal powder formulations of thalidomide were designed and studied to be used by persons affected by hereditary hemorrhagic telangiectasia as a complementary anti-epistaxis therapy, with the goal of sustaining the effect obtained with thalidomide oral treatment after its discontinuation for adverse effects." | 3.83 | Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. ( Bettini, R; Bortolotti, F; Buttini, F; Chiapponi, V; Colombo, G; Colombo, P; Danesino, C; Invernizzi, R; Pagella, F; Quaglia, F; Rossi, A; Russo, P; Sonvico, F, 2016) |
| " We report here that treatment with thalidomide reduced the severity and frequency of nosebleeds (epistaxis) in the majority of a small group of subjects with HHT tested." | 3.76 | Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. ( Arthur, HM; Bréant, C; Disch, F; Eichmann, A; Freitas, C; Larrivée, B; Lebrin, F; Mager, JJ; Martin, S; Mathivet, T; Mummery, CL; Raymond, K; Snijder, RJ; Srun, S; Thomas, JL; van den Brink, S; Westermann, CJ, 2010) |
| "Although epistaxis is usually presented in childhood (mean age 11 ± 7." | 1.48 | Clinical features and treatment of hereditary hemorrhagic telangiectasia. ( Li, S; Wang, SJ; Zhao, YQ, 2018) |
| "Thalidomide was recently reported to reduce the severity and frequency of epistaxes in patients with hereditary haemorrhagic telangiectasia (HHT)." | 1.37 | Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. ( Hermans, C; Lambert, C; Penaloza, A; Vekemans, MC, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, J | 1 |
| Chen, X | 1 |
| Zhu, B | 1 |
| Ye, H | 1 |
| Zhang, W | 1 |
| Guan, J | 1 |
| Su, K | 1 |
| Halderman, AA | 1 |
| Ryan, MW | 1 |
| Clark, C | 1 |
| Sindwani, R | 1 |
| Reh, DD | 1 |
| Poetker, DM | 1 |
| Invernizzi, R | 3 |
| Marple, BF | 1 |
| Baysal, M | 1 |
| Ümit, EG | 1 |
| Kırkızlar, HO | 1 |
| Özdöver, AC | 1 |
| Demir, AM | 1 |
| Li, S | 1 |
| Wang, SJ | 1 |
| Zhao, YQ | 1 |
| Harrison, L | 1 |
| Kundra, A | 1 |
| Jervis, P | 1 |
| Buscarini, E | 1 |
| Botella, LM | 1 |
| Geisthoff, U | 1 |
| Kjeldsen, AD | 1 |
| Mager, HJ | 1 |
| Pagella, F | 3 |
| Suppressa, P | 1 |
| Zarrabeitia, R | 1 |
| Dupuis-Girod, S | 1 |
| Shovlin, CL | 1 |
| Engelen, ET | 1 |
| van Galen, KP | 1 |
| Schutgens, RE | 1 |
| Franchini, M | 1 |
| Lippi, G | 1 |
| Quaglia, F | 2 |
| Klersy, C | 1 |
| Ornati, F | 1 |
| Chu, F | 1 |
| Matti, E | 1 |
| Spinozzi, G | 1 |
| Plumitallo, S | 1 |
| Grignani, P | 1 |
| Olivieri, C | 1 |
| Bastia, R | 1 |
| Bellistri, F | 1 |
| Danesino, C | 2 |
| Benazzo, M | 1 |
| Balduini, CL | 1 |
| Colombo, G | 1 |
| Bortolotti, F | 1 |
| Chiapponi, V | 1 |
| Buttini, F | 1 |
| Sonvico, F | 1 |
| Russo, P | 1 |
| Bettini, R | 1 |
| Colombo, P | 1 |
| Rossi, A | 1 |
| Lebrin, F | 1 |
| Srun, S | 1 |
| Raymond, K | 1 |
| Martin, S | 1 |
| van den Brink, S | 1 |
| Freitas, C | 1 |
| Bréant, C | 1 |
| Mathivet, T | 1 |
| Larrivée, B | 1 |
| Thomas, JL | 1 |
| Arthur, HM | 1 |
| Westermann, CJ | 1 |
| Disch, F | 1 |
| Mager, JJ | 1 |
| Snijder, RJ | 1 |
| Eichmann, A | 1 |
| Mummery, CL | 1 |
| Akhurst, RJ | 1 |
| Penaloza, A | 1 |
| Vekemans, MC | 1 |
| Lambert, C | 1 |
| Hermans, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)[NCT01485224] | Phase 2 | 31 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
4 reviews available for thalidomide and Epistaxis
| Article | Year |
|---|---|
Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study.
Topics: Adult; Aged; Epistaxis; Female; Humans; Male; Middle Aged; Severity of Illness Index; Telangiectasia | 2017 |
Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review.
Topics: Administration, Oral; Administration, Topical; Angiogenesis Inhibitors; Epistaxis; Estriol; Estrogen | 2018 |
The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.
Topics: Angiogenesis Inhibitors; Epistaxis; Humans; Recurrence; Telangiectasia, Hereditary Hemorrhagic; Thal | 2018 |
Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature.
Topics: Aged; Angiodysplasia; Databases, Factual; Epistaxis; Female; Gastrointestinal Hemorrhage; Humans; Me | 2015 |
1 trial available for thalidomide and Epistaxis
| Article | Year |
|---|---|
Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.
Topics: Aged; Epistaxis; Female; Humans; Italy; Male; Middle Aged; Quality of Life; Telangiectasia, Heredita | 2015 |
8 other studies available for thalidomide and Epistaxis
| Article | Year |
|---|---|
Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life
Topics: Adult; Aged; Epistaxis; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Quality of Life | 2019 |
Clinical features and treatment of hereditary hemorrhagic telangiectasia.
Topics: Adult; Angiogenesis Inhibitors; Arteriovenous Malformations; Delayed Diagnosis; Epistaxis; Female; H | 2018 |
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
Topics: Adolescent; Adult; Bevacizumab; Epistaxis; Female; Hemorrhage; Humans; Male; Retrospective Studies; | 2019 |
Thalidomide for hereditary haemorrhagic telangiectasia.
Topics: Epistaxis; Humans; Telangiectasia, Hereditary Hemorrhagic; Thalidomide | 2015 |
Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia.
Topics: Administration, Intranasal; Animals; beta-Cyclodextrins; Chemistry, Pharmaceutical; Drug Carriers; E | 2016 |
Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.
Topics: Aged; Animals; Blood Vessels; Disease Models, Animal; Endothelial Cells; Epistaxis; Hemoglobins; Hum | 2010 |
Taking thalidomide out of rehab.
Topics: Animals; Endothelial Cells; Epistaxis; Humans; Mice; Neovascularization, Physiologic; Telangiectasia | 2010 |
Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia.
Topics: Activin Receptors, Type II; Contraindications; Epistaxis; Female; Humans; Middle Aged; Mutation; Tel | 2011 |